Showing 5891-5900 of 6035 results for "".
- Aerie Pharmaceuticals Reports Topline Results From Rhopressa Mechanism of Action Studyhttps://modernod.com/news/aerie-pharmaceuticals-reports-topline-result-from-rhopressa-mechanism-of-action-study/2479942/Aerie Pharmaceuticals announced topline efficacy results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of Rhopressa (netarsudil ophthalmic solution 0.02%) on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. While seve
- Breakthrough in AI Technology to Improve Care for Patientshttps://modernod.com/news/breakthrough-in-ai-technology-to-improve-care-for-patients/2479943/Two years ago, Moorfields Eye Hospital NHS Foundation Trust and DeepMind Health came together to announce a 5-year partnership to explore whether artificial intelligence (AI) technology could help clinicians improve care for patients. Researchers from Moorfields and the UCL Institute of Op
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 17th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-17th-time/2479945/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education and patient care, Basco
- Astellas Announces Acquisition of Quethera, Maker of Gene Therapy Program for Glaucomahttps://modernod.com/news/astellas-announces-acquisition-of-quethera-maker-of-gene-therapy-program-for-glaucoma/2479949/Astellas Pharma has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma. Under the terms of the agreement, Astellas may pay up to £85 million ($1
- Ivantis Receives FDA Approval for the Hydrus Microstent for Minimally Invasive Glaucoma Surgery (MIGS)https://modernod.com/news/ivantis-receives-fda-approval-for-the-hydrus-microstent-device-for-minimally-invasive-glaucoma-surgery-migs/2479950/Ivantis announced that it has received FDA approval for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. “The Hydrus represents a unique next-generation
- Australian Research Lifts the Lid on Lipids to Prevent Dry Eyehttps://modernod.com/news/australian-research-lifts-the-lid-on-lipids-to-prevent-dry-eye/2479951/Australian researchers have made an important breakthrough in understanding the composition of the tear film that protects the eyes, leading to more effective treatments for dry eye disease. The project was a collaboration between researchers at University of Wollongong, QUT and the Univ
- Eye Health America Acquires Montgomery & Riddle Eyecare and The Surgery and Laser Center at Professional Parkhttps://modernod.com/news/eye-health-america-acquires-montgomery-riddle-eyecare-in-south-carolina/2479957/Eye Health America (EHA) announced its acquisition of Montgomery & Riddle Eyecare and The Surgery & Laser Center at Professional Park, an eye care provider in South Carolina. Terms of the deal were not disclosed. The acquisition of Montgomery & Riddle Eyecare strengthens
- Ocutech Introduces New Ves Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/Following 6 years of development and testing, Ocutech has introduced its new VES Falcon Autofocus Bioptic Telescope, the company’s next generation autofocusing bioptic for the visually impaired. The Falcon is in initial limited release with select low-vision specialists in the United
- International Sports Vision Association Announces Appointment of Gary Esterow as Executive Directorhttps://modernod.com/news/international-sports-vision-association-announces-appointment-of-gary-esterow-as-executive-director/2479964/The International Sports Vision Association (ISVA), an organization of optometrists, athletic trainers, therapists, physicians and sports teams dedicated to evaluating, training, and improving vision performance in athletes, announced the appointment of Gary Esterow as Executive Director.
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft